InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,471.05
(
1.16%
)
US TECH 100
18,183.60
(
1.31%
)
Dow Jones
40,829.59
(
1.20%
)
Brent Oil
71.60
(
0.08%
)
Bitcoin
56,857.54
(
3.62%
)
Post# of 253071
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 838
Posts 120396
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 88680

Friday, 02/18/2011 1:19:10 PM

Friday, February 18, 2011 1:19:10 PM

Post# of 253071
CHMP approves NVS’ Rasilamlo (Rasilez+Amlodipine) for hypertension:

http://www.reuters.com/article/2011/02/18/norvartis-idUSLDE71H1ER20110218

In the US, this product was approved in Aug 2010 (#msg-53782319) and is called Tekamlo (Tekturna+Amlodipine). A 3-in-1 variation with HCTZ added was approved in Dec 2010 (#msg-58062858) and is called Amturnide (Amlodipine+Tekturna+Hydrochlorothiazide).

Standalone sales of Tekturna/Rasilez have been disappointing; maybe these combination products will be material contributors.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up